argenx SE (ARGX): Price and Financial Metrics
argenx SE (ARGX)
Today's Latest Price: $252.74 USD
Updated Oct 29 1:35pm
Add ARGX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ARGX Stock Summary
- ARGX's price/sales ratio is 140.27; that's higher than the P/S ratio of 97.84% of US stocks.
- Over the past twelve months, ARGX has reported earnings growth of 640.7%, putting it ahead of 97.52% of US stocks in our set.
- As for revenue growth, note that ARGX's revenue has grown 374.98% over the past 12 months; that beats the revenue growth of 98.19% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Argenx Se, a group of peers worth examining would be DNLI, FATE, PRQR, ASND, and AUTL.
- ARGX's SEC filings can be seen here. And to visit Argenx Se's official web site, go to www.argenx.com.
ARGX Stock Price Chart Interactive Chart >
ARGX Price/Volume Stats
| Current price | $252.74 | 52-week high | $284.00 |
| Prev. close | $254.34 | 52-week low | $103.75 |
| Day low | $249.57 | Volume | 68,475 |
| Day high | $253.59 | Avg. volume | 176,318 |
| 50-day MA | $248.09 | Dividend yield | N/A |
| 200-day MA | $198.13 | Market Cap | 11.88B |
argenx SE (ARGX) Company Bio
arGEN-X N.V., a clinical-stage biopharmaceutical company, focuses on creating and developing therapeutic antibodies for the treatment of cancer and autoimmune diseases. The company was founded in 2008 and is based in Breda, Netherlands.
ARGX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $252.74 | $2687.23 | 957% |
We started the process of determining a valid price forecast for Argenx Se with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Argenx Se ranked in the 84th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Argenx Se ended up being:
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 1.85% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Argenx Se's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -1,274.91. This coverage rate is greater than that of just 0.38% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- As a business, Argenx Se experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 936% |
| 1% | 946% |
| 2% | 957% |
| 3% | 967% |
| 4% | 977% |
| 5% | 988% |
Want more companies with a valuation profile/forecast similar to that of Argenx Se? See HCA, NVCR, NHC, FVE, and VMD.
Loading social stream, please wait...